Nishina T, et al. - Using data from the G-SOX study, the researchers examined early tumor shrinkage (ETS) and depth of response (DpR) comparing S-1 plus oxaliplatin with S-1 plus cisplatin as first-line treatment for advanced gastric cancer (AGC). They assessed ETS as percent decrease in the sum of the longest diameters of the target lesions at the first evaluation of week 6 compared to baseline. In total 632 patients who had the first tumor evaluation were analyzed out of 685 subjects recruited in the G-SOX study. The findings from the present study suggested that ETS and DpR could be predictors for progression-free survival and overall survival in AGC patients receiving the first-line therapy.